ArticleScientific reports2025
The associations of calf circumference and cardiovascular and all-cause mortality among population with chronic kidney disease stages 3-5.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Previous studies have described the association between calf circumference (CC) and chronic kidney disease (CKD). We aim to evaluate the associations between CC and cardiovascular and all-cause mortality in patients with CKD stages 3-5. Data on CKD were sourced from the National Health and Nutritional Examination Survey (NHANES) 1999-2004. The population was stratified into three groups based on their CC tertile. Kaplan-Meier method with log-rank tests for significance was used for survival analysis. Weighted Cox proportional hazards regression models were employed to estimate the hazard ratios (HRs) for cardiovascular and all-cause mortality. The potential nonlinear relationship between CC and mortality was assessed using restricted cubic spline (RCS) models. Subgroup and sensitivity analyses were conducted to strengthen the results. A total of 1166 patients were eventually included in this study. After a mean follow-up of 127.78 months, a total of 922 all-cause deaths were recorded, with 515 of them attributed to cardiovascular diseases. The Kaplan-Meier curve indicated a significant difference in overall survival between the three groups (log-rank test, P < 0.0001). Compared to the CC > 38.5 group, participants in the CC < 35.0 group had HR of 2.05 (1.44, 2.93) for all-cause mortality and 1.58 (0.75, 3.33) for cardiovascular mortality, respectively. We observed a significant nonlinear relationship between CC and cardiovascular and all-cause mortality (P-nonlinear < 0.05). Subgroup analysis further validated our results and demonstrated that the impact of CC on prognosis varies according to distinct characteristics. Sensitivity analyses yielded similar results for both all-cause and cardiovascular mortality. A reduced CC is correlated with a poorer prognosis in CKD stages 3-5 patients, suggesting its potential utility as an innovative prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.